Mesoblast Limited vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $213.44 (market cap $39.15B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 22.4× Mesoblast Limited's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days on average.
| MESO | TTWO | |
|---|---|---|
Market Cap | $1.75B | $39.15B |
Volume | 239,027 | 2,708,429 |
Sector | Health | Technology |
52-Week High | $20.96 | $262.29 |
52-Week Low | $13.19 | $189.69 |
Typical Hold Time | 15 Days | 111 Days |
Enterprise Value | $1.83B | $40.27B |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Take-Two Interactive (TTWO) trades at $209.37, up 2.63% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026, while the company reaffirmed the GTA VI launch date for November 19, 2026. Financials reveal negative net income margins and elevated debt levels, though revenue growth is projected to $6.7B in 2026. The stock is near its pivot point of $209, with support at $206 and resistance at $212.
The outlook hinges on GTA VI's successful launch driving revenue growth and profitability improvements. Risks include execution challenges, competitive pressures, and high valuation multiples. Analyst optimism, with a $292.30 price target, suggests significant upside if operational targets are met, but investors must weigh near-term losses against long-term game release catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →